Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2020

Open Access 01-12-2020 | Pompe Disease | Research

Distal muscle weakness is a common and early feature in long-term enzyme-treated classic infantile Pompe patients

Authors: J. J. A. van den Dorpel, E. Poelman, L. Harlaar, H. A. van Kooten, L. J. van der Giessen, P. A. van Doorn, A. T. van der Ploeg, J. M. P. van den Hout, N. A. M. E. van der Beek

Published in: Orphanet Journal of Rare Diseases | Issue 1/2020

Login to get access

Abstract

Background

Enzyme replacement therapy (ERT; alglucosidase alfa) has improved the prospects for patients with classic infantile Pompe disease considerably. However, over time we noticed that many of these children exhibit distal muscle weakness at an early age, which is in contrast to the primarily proximal and axial muscle weakness in patients with late-onset Pompe disease. This was reason to study the prevalence and severity of distal muscle weakness, and the sequence of muscle involvement over time in patients that had learned to walk under ERT.

Methods

In this prospective, single-center cohort study, we studied 16 classic infantile patients. We used video recordings that were made during regular standardized assessments to investigate distal muscle function (active dorsiflexion of the feet during walking; ability to use a pincer grasp/actively extend the fingers) and proximal muscle function (standing up from a supine position; raising the arms above the head).

Results

Median age at start of ERT was 3.2 months (0.1–5.8 months), median age at study end was 5.6 years (2.9–18.2 years). Six patients (6/16, 38%) initially had no evident signs of distal muscle weakness and developed a gait with active dorsiflexion of the feet. The other 10 patients never exhibited active dorsiflexion of the feet during walking. At study-end two patients showed no loss of distal muscle function. A subset of five patients (5/16, 31%) developed also weakness of the hands, particularly of the extensors of the 3rd and 4th digit.

Conclusions

We found that the majority (14/16, 88%) of patients who had learned to walk exhibited distal muscle weakness of the lower extremities, while a subset (5/16, 31%) also developed weakness of the hands. The distal muscle weakness was often more serious than, and preceded the development of, the proximal muscle weakness.
Literature
1.
go back to reference Reuser AJ, Hirschhorn R, Kroos MA. Pompe disease: Glycogen storage disease type II, Acid alpha-glucosidase (acid maltase) deficiency. McGraw Hill: The Online Metabolic & Molecular Bases of Inherited Disease (OMMBID); 2018. [cited 8 October 2018]. Available from: https://ommbid.mhmedical.com. Reuser AJ, Hirschhorn R, Kroos MA. Pompe disease: Glycogen storage disease type II, Acid alpha-glucosidase (acid maltase) deficiency. McGraw Hill: The Online Metabolic & Molecular Bases of Inherited Disease (OMMBID); 2018. [cited 8 October 2018]. Available from: https://​ommbid.​mhmedical.​com.
2.
go back to reference van der Ploeg AT, Reuser AJ. Pompe’s disease. Lancet. 2008;372(9646):1342–53.CrossRef van der Ploeg AT, Reuser AJ. Pompe’s disease. Lancet. 2008;372(9646):1342–53.CrossRef
3.
go back to reference Gungor D, Reuser AJ. How to describe the clinical spectrum in Pompe disease? Am J Med Genet A. 2013;161A(2):399–400.CrossRef Gungor D, Reuser AJ. How to describe the clinical spectrum in Pompe disease? Am J Med Genet A. 2013;161A(2):399–400.CrossRef
4.
go back to reference van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, et al. The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112(2):332–40.CrossRef van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, et al. The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112(2):332–40.CrossRef
5.
go back to reference Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006;148(5):671–6.CrossRef Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006;148(5):671–6.CrossRef
6.
go back to reference Winkel LP, Hagemans ML, van Doorn PA, Loonen MC, Hop WJ, Reuser AJ, et al. The natural course of non-classic Pompe’s disease; a review of 225 published cases. J Neurol. 2005;252(8):875–84.CrossRef Winkel LP, Hagemans ML, van Doorn PA, Loonen MC, Hop WJ, Reuser AJ, et al. The natural course of non-classic Pompe’s disease; a review of 225 published cases. J Neurol. 2005;252(8):875–84.CrossRef
7.
go back to reference van der Beek NA, de Vries JM, Hagemans ML, Hop WC, Kroos MA, Wokke JH, et al. Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet J Rare Dis. 2012;7:88.CrossRef van der Beek NA, de Vries JM, Hagemans ML, Hop WC, Kroos MA, Wokke JH, et al. Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet J Rare Dis. 2012;7:88.CrossRef
8.
go back to reference Van der Beek NA, Hagemans ML, Reuser AJ, Hop WC, Van der Ploeg AT, Van Doorn PA, et al. Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscul Disord. 2009;19(2):113–7.CrossRef Van der Beek NA, Hagemans ML, Reuser AJ, Hop WC, Van der Ploeg AT, Van Doorn PA, et al. Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscul Disord. 2009;19(2):113–7.CrossRef
9.
go back to reference Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet. 2000;356(9227):397–8.CrossRef Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet. 2000;356(9227):397–8.CrossRef
10.
go back to reference Van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De Klerk JB, Loonen MC, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics. 2004;113(5):e448–57.CrossRef Van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De Klerk JB, Loonen MC, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics. 2004;113(5):e448–57.CrossRef
11.
go back to reference Kishnani PS, Corzo D, Leslie ND, Gruskin D, Van der Ploeg A, Clancy JP, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009;66(3):329–35.CrossRef Kishnani PS, Corzo D, Leslie ND, Gruskin D, Van der Ploeg A, Clancy JP, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009;66(3):329–35.CrossRef
12.
go back to reference Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007;68(2):99–109.CrossRef Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007;68(2):99–109.CrossRef
13.
go back to reference Chakrapani A, Vellodi A, Robinson P, Jones S, Wraith JE. Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience. J Inherit Metab Dis. 2010;33(6):747–50.CrossRef Chakrapani A, Vellodi A, Robinson P, Jones S, Wraith JE. Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience. J Inherit Metab Dis. 2010;33(6):747–50.CrossRef
14.
go back to reference Hahn A, Praetorius S, Karabul N, Diessel J, Schmidt D, Motz R, et al. Outcome of patients with classical infantile pompe disease receiving enzyme replacement therapy in Germany. JIMD Rep. 2015;20:65–75.CrossRef Hahn A, Praetorius S, Karabul N, Diessel J, Schmidt D, Motz R, et al. Outcome of patients with classical infantile pompe disease receiving enzyme replacement therapy in Germany. JIMD Rep. 2015;20:65–75.CrossRef
15.
go back to reference van Gelder CM, Poelman E, Plug I, Hoogeveen-Westerveld M, van der Beek N, Reuser AJJ, et al. Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study. J Inherit Metab Dis. 2016;39(3):383–90.CrossRef van Gelder CM, Poelman E, Plug I, Hoogeveen-Westerveld M, van der Beek N, Reuser AJJ, et al. Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study. J Inherit Metab Dis. 2016;39(3):383–90.CrossRef
16.
go back to reference Case LE, Beckemeyer AA, Kishnani PS. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations. Am J Med Genet C: Semin Med Genet. 2012;160C(1):69–79.CrossRef Case LE, Beckemeyer AA, Kishnani PS. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations. Am J Med Genet C: Semin Med Genet. 2012;160C(1):69–79.CrossRef
17.
go back to reference Prater SN, Banugaria SG, DeArmey SM, Botha EG, Stege EM, Case LE, et al. The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med. 2012;14(9):800–10.CrossRef Prater SN, Banugaria SG, DeArmey SM, Botha EG, Stege EM, Case LE, et al. The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med. 2012;14(9):800–10.CrossRef
18.
go back to reference Muller CW, Jones HN, O’Grady G, Suárez AH, Heller JH, Kishnani PS. Language and speech function in children with infantile Pompe disease. J Pediatr Neurol. 2009;7(2):147–56. Muller CW, Jones HN, O’Grady G, Suárez AH, Heller JH, Kishnani PS. Language and speech function in children with infantile Pompe disease. J Pediatr Neurol. 2009;7(2):147–56.
19.
go back to reference Sutherland DH, Olshen R, Cooper L, Woo SL. The development of mature gait. J Bone Joint Surg Am. 1980;62(3):336–53.CrossRef Sutherland DH, Olshen R, Cooper L, Woo SL. The development of mature gait. J Bone Joint Surg Am. 1980;62(3):336–53.CrossRef
20.
go back to reference Schanzer A, Gorlach J, Claudi K, Hahn A. Severe distal muscle involvement and mild sensory neuropathy in a boy with infantile onset Pompe disease treated with enzyme replacement therapy for 6 years. Neuromuscul Disord. 2019;29(6):477–82.CrossRef Schanzer A, Gorlach J, Claudi K, Hahn A. Severe distal muscle involvement and mild sensory neuropathy in a boy with infantile onset Pompe disease treated with enzyme replacement therapy for 6 years. Neuromuscul Disord. 2019;29(6):477–82.CrossRef
21.
go back to reference Sobotta J, Paulsen F, Waschke J, Hombach-Klonisch S, Klonisch T. Sobotta atlas of human anatomy, vol. 1. München: Elsevier/Urban & Fischer; 2013. Sobotta J, Paulsen F, Waschke J, Hombach-Klonisch S, Klonisch T. Sobotta atlas of human anatomy, vol. 1. München: Elsevier/Urban & Fischer; 2013.
22.
go back to reference Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99(1):26–33.CrossRef Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99(1):26–33.CrossRef
23.
go back to reference van Gelder CM, Hoogeveen-Westerveld M, Kroos MA, Plug I, van der Ploeg AT, Reuser AJ. Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease. J Inherit Metab Dis. 2015;38(2):305–14.CrossRef van Gelder CM, Hoogeveen-Westerveld M, Kroos MA, Plug I, van der Ploeg AT, Reuser AJ. Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease. J Inherit Metab Dis. 2015;38(2):305–14.CrossRef
24.
go back to reference Muller-Felber W, Horvath R, Gempel K, Podskarbi T, Shin Y, Pongratz D, et al. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord. 2007;17(9–10):698–706.CrossRef Muller-Felber W, Horvath R, Gempel K, Podskarbi T, Shin Y, Pongratz D, et al. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord. 2007;17(9–10):698–706.CrossRef
25.
go back to reference van der Meijden JC, Kruijshaar ME, Harlaar L, Rizopoulos D, van der Beek N, van der Ploeg AT. Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy. J Inherit Metab Dis. 2018;41:1205–14.CrossRef van der Meijden JC, Kruijshaar ME, Harlaar L, Rizopoulos D, van der Beek N, van der Ploeg AT. Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy. J Inherit Metab Dis. 2018;41:1205–14.CrossRef
26.
go back to reference Montagnese F, Barca E, Musumeci O, Mondello S, Migliorato A, Ciranni A, et al. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment. J Neurol. 2015;262(4):968–78.CrossRef Montagnese F, Barca E, Musumeci O, Mondello S, Migliorato A, Ciranni A, et al. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment. J Neurol. 2015;262(4):968–78.CrossRef
27.
go back to reference Pichiecchio A, Rossi M, Cinnante C, Colafati GS, De Icco R, Parini R, et al. Muscle MRI of classic infantile pompe patients: fatty substitution and edema-like changes. Muscle Nerve. 2017;55(6):841–8.CrossRef Pichiecchio A, Rossi M, Cinnante C, Colafati GS, De Icco R, Parini R, et al. Muscle MRI of classic infantile pompe patients: fatty substitution and edema-like changes. Muscle Nerve. 2017;55(6):841–8.CrossRef
28.
go back to reference Mancall EL, Aponte GE, Berry RG. Pompe’s disease (diffuse Glycogenosis) with neuronal storage. J Neuropathol Exp Neurol. 1965;24:85–96.CrossRef Mancall EL, Aponte GE, Berry RG. Pompe’s disease (diffuse Glycogenosis) with neuronal storage. J Neuropathol Exp Neurol. 1965;24:85–96.CrossRef
29.
go back to reference Gambetti P, DiMauro S, Baker L. Nervous system in Pompe’s disease. Ultrastructure and biochemistry. J Neuropathol Exp Neurol. 1971;30(3):412–30.CrossRef Gambetti P, DiMauro S, Baker L. Nervous system in Pompe’s disease. Ultrastructure and biochemistry. J Neuropathol Exp Neurol. 1971;30(3):412–30.CrossRef
30.
go back to reference Martin JJ, de Barsy T, van Hoof F, Palladini G. Pompe’s disease: an inborn lysosomal disorder with storage of glycogen. A study of brain and striated muscle. Acta Neuropathol. 1973;23(3):229–44.CrossRef Martin JJ, de Barsy T, van Hoof F, Palladini G. Pompe’s disease: an inborn lysosomal disorder with storage of glycogen. A study of brain and striated muscle. Acta Neuropathol. 1973;23(3):229–44.CrossRef
31.
go back to reference Burrow TA, Bailey LA, Kinnett DG, Hopkin RJ. Acute progression of neuromuscular findings in infantile Pompe disease. Pediatr Neurol. 2010;42(6):455–8.CrossRef Burrow TA, Bailey LA, Kinnett DG, Hopkin RJ. Acute progression of neuromuscular findings in infantile Pompe disease. Pediatr Neurol. 2010;42(6):455–8.CrossRef
32.
go back to reference Hobson-Webb LD, Dearmey S, Kishnani PS. The clinical and electrodiagnostic characteristics of Pompe disease with post-enzyme replacement therapy findings. Clin Neurophysiol. 2011;122(11):2312–7.CrossRef Hobson-Webb LD, Dearmey S, Kishnani PS. The clinical and electrodiagnostic characteristics of Pompe disease with post-enzyme replacement therapy findings. Clin Neurophysiol. 2011;122(11):2312–7.CrossRef
33.
go back to reference Poelman E, Hoogeveen-Westerveld M, Kroos-de Haan MA, van den Hout JMP, Bronsema KJ, van de Merbel NC, et al. High sustained antibody titers in patients with classic infantile Pompe disease following immunomodulation at start of enzyme replacement therapy. J Pediatr. 2018;195:236–43 e3.CrossRef Poelman E, Hoogeveen-Westerveld M, Kroos-de Haan MA, van den Hout JMP, Bronsema KJ, van de Merbel NC, et al. High sustained antibody titers in patients with classic infantile Pompe disease following immunomodulation at start of enzyme replacement therapy. J Pediatr. 2018;195:236–43 e3.CrossRef
34.
go back to reference Van der Meulen BF, Ruiter SAJ, Spelberg HCL, Smrkovsky M. Bayley scales of infant development-II. Dutch version. Lisse: Swets; 2002. Van der Meulen BF, Ruiter SAJ, Spelberg HCL, Smrkovsky M. Bayley scales of infant development-II. Dutch version. Lisse: Swets; 2002.
35.
go back to reference Bayley N. Manual for the Bayley scales of infant development. San Antonio: The Psychological Corporation; 1993. Bayley N. Manual for the Bayley scales of infant development. San Antonio: The Psychological Corporation; 1993.
36.
go back to reference Laurent de Angulo MS. Ontwikkelingsonderzoek in de jeugdgezondheidszorg : het Van Wiechenonderzoek: de Baecke-Fassaert motoriektest. Assen: Koninklijke Van Gorcum; 2008. Laurent de Angulo MS. Ontwikkelingsonderzoek in de jeugdgezondheidszorg : het Van Wiechenonderzoek: de Baecke-Fassaert motoriektest. Assen: Koninklijke Van Gorcum; 2008.
Metadata
Title
Distal muscle weakness is a common and early feature in long-term enzyme-treated classic infantile Pompe patients
Authors
J. J. A. van den Dorpel
E. Poelman
L. Harlaar
H. A. van Kooten
L. J. van der Giessen
P. A. van Doorn
A. T. van der Ploeg
J. M. P. van den Hout
N. A. M. E. van der Beek
Publication date
01-12-2020
Publisher
BioMed Central
Keyword
Pompe Disease
Published in
Orphanet Journal of Rare Diseases / Issue 1/2020
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-020-01482-w

Other articles of this Issue 1/2020

Orphanet Journal of Rare Diseases 1/2020 Go to the issue